A publicly held library of investigational drugs available for academic combination trials
A government or charity holds stocks of experimental cancer drugs under standing agreements, so academic doctors can test combinations without negotiating with each company separately.
NCI's CTEP investigational agent programme has run for decades but covers a narrow set of agents and mostly US sites. A broader, international formulary of investigational and newly approved agents held under pre-agreed terms (including pricing for trial use of approved drugs) would let cooperative groups design combination trials from a menu rather than by bilateral pleading.
- Too many combinations to test · There are thousands of possible drug pairs and sequences. Trials can test a few dozen a year.
- Secrecy and intellectual property block collaboration · Companies with complementary drugs rarely test them together, and data that could answer questions stays locked up.
Pages like this
not linked directly; found by shared links- IdeaA standard cross-company combination agreement that takes weeks, not years, to sign
Shares Secrecy and intellectual property block collaboration, Too many combinations to test, National Cancer Institute (NIH).
- IdeaA patent pool for combination method-of-use claims
Shares Secrecy and intellectual property block collaboration, Too many combinations to test.
- IdeaA permanent neutral non-profit sponsor for multi-company platform trials
Shares SWOG Cancer Research Network, Secrecy and intellectual property block collaboration, Too many combinations to test.
- IdeaFollow every trial participant for 30 years through registry linkage
Shares ECOG-ACRIN Cancer Research Group, SWOG Cancer Research Network.
- IdeaA regulator-endorsed standard contract for inter-company combination trials
Shares Secrecy and intellectual property block collaboration, Too many combinations to test.
- IdeaEvery approved cancer drug ships with a public combination-readiness data pack
Shares Secrecy and intellectual property block collaboration, Too many combinations to test.
- IdeaA legal right to obtain marketed cancer drugs at cost for combination trials
Shares Secrecy and intellectual property block collaboration, Too many combinations to test.
- IdeaA shared compound library that rare cancer researchers can actually use
Shares Secrecy and intellectual property block collaboration, National Cancer Institute (NIH).